Future Directions and Unmet Needs in in EGFR-Mutant NSCLC

Heather Wakelee, MD, and Helena Yu, MD, highlight ongoing challenges and future directions in the field. They discuss the potential for biomarkers beyond EGFR and TP53 to further refine treatment decisions and identify novel therapeutic targets under investigation. The conversation concludes with a focus on the types of data that could most meaningfully impact clinical practice, including studies that better define optimal sequencing and guide treatment de-escalation.